[Federal Register Volume 60, Number 237 (Monday, December 11, 1995)]
[Notices]
[Pages 63538-63539]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-30005]



-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES

Prospective Grant of Exclusive License: Activity Dependent 
Neurotropic Factor

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR 404.7(a)(1)(i) that the National Institutes of Health (NIH), 
Department of Health and Human Services, is contemplating the grant of 
an exclusive world-wide license to practice the inventions embodied in 
U.S. Patent Applications 07/688,087, 07/871,973 and 08/324,297 and 
corresponding foreign patent applications entitled, ``Activity 
Dependent Neurotropic Factor'' to Pfizer Inc. of New York, NY. The 
patent rights in these inventions have been assigned to the United 
States of America.
    The prospective exclusive license will be royalty-bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. 
The prospective exclusive license may be granted unless within sixty 
(60) days from the date of this published notice, NIH receives written 
evidence and argument that establishes that the grant of the license 
would not be consistent with the requirements of 35 U.S.C. 209 and 37 
CFR 404.7.
    The present patent applications cover a purified non-neuronal 
activity-dependent neurotropic factor (ADNF) protein that increases the 
growth and survival of developing spinal cord neurons and prevents 
neuronal cell death. It may have extensive use in treating various 
neurological deficiencies, such as Alzheimer's disease, Huntington's 
disease, diabetic neuropathy, spinal cord injury, HIV encephalopathy 
and stroke.

ADDRESSES: Requests for copies of the patent applications, inquiries, 
comments and other materials relating to the contemplated licenses 
should be directed to: Girish C. Barua, Ph.D., 

[[Page 63539]]
Technology Licensing Specialist, Office of Technology Transfer, 
National Institutes of Health, 6011 Executive Boulevard, Suite 325, 
Rockville, Maryland 20852-3804; telephone: (301) 496-7735 ext. 263; 
facsimile: (301) 402-0220. A signed Confidential Disclosure Agreement 
will be required to receive copies of the patent applications. 
Applications for a license in the field of use filed in response to 
this notice will be treated as objections to the grant of the 
contemplated licenses.
    Only written comments and/or applications for a license which are 
received by NIH on or before February 9, 1996 will be considered. 
Comments and objections submitted to this notice will not be made 
available for public inspection and, to the extent permitted by law, 
will not be released under the Freedom of Information Act, 5 U.S.C. 
552.

    Dated: November 28, 1995.
Barbara M. McGarey,
Deputy Director, Office of Technology Transfer.
[FR Doc. 95-30005 Filed 12-8-95; 8:45 am]
BILLING CODE 4140-01-M